Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT06835179	TitleSBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.	Fase Fase 2	Date Added 2025-02-19	Ubicación	Prior IO Allowed No	CRC-directed Sí	Status Aún no se ha contratado	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06841159	TitlePersonalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2025-03-25	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06850103	TitleSCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer with Oligometastases	Fase Fase 2	Date Added 2025-03-25	Ubicación	Prior IO Allowed No	CRC-directed Sí	Status Aún no se ha contratado	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06856837	Title– IKF/AIO-QUINTIS – Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases	Fase Fase 2	Date Added 2025-03-04	Ubicación Austria Alemania	Prior IO Allowed No	CRC-directed Sí	Status Aún no se ha contratado	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06764680	TitleOral Chemotherapy, Targeted Therapy and Immunotherapy With/without Radiotherapy As 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer	Fase Fase 2	Date Added 2025-01-08	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Aún no se ha contratado	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06412198	TitleA Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations	Fase Phase 1, Phase 2	Date Added 2024-05-14	Ubicación Massachusetts, United States Texas, United States	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Adagrasib, cemiplimab, cetuximab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06415851	TitleChemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab	Fase Fase 2	Date Added 2024-05-15	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Aún no se ha contratado	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06455254	TitleCadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM	Fase Fase 2	Date Added 2024-06-12	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT05726864	TitleA Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors	Fase Phase 1, Phase 2	Date Added 2023-02-14	Ubicación Arizona, United States California, United States Colorado, United States Florida, United States Georgia, United States Iowa, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas ELI-002 7P	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05768503	TitleComparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC	Fase Fase 3	Date Added 2023-03-14	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Control Rx, Experimental drug	Etiquetas MSS/ MMRp

Showing 161 to 170 of 299 entries